To whom SII confirms it’s deal?
Poonawalla said to Bloomberg that
“People today are really puzzled why we are the only ones who can make Covid-19 at this scale, and that’s because I had the vision, and we put in all the money, to just build.”
SII confirms it’s vaccine with cheap and at affordable price!
On August 7, 2020, SII announced the production of 100 million COVID-19 vaccine doses for India, low-income and middle-income nations. These doses are set to be shipped as early as 2021. Although it has made a deal with AstraZeneca, the company may possibly produce other vaccine models as well. As long as the deal does not violate the other agreements, SII may support scalability of different Corona(COVID-19) vaccines. If both vaccines attained WHO Prequalification and full licensure, the ceiling price per dose is set to $3.The partnership with Gavi and the Bill and Melinda Gates foundation pushed both scalable manufacturing and a low ceiling price. While the complete list of countries was not revealed in the press release, the $3 per vaccine dose is assigned to 92 countries in Gavi’s COVAX Advance Market Commitment. Recently, CNBC reported the estimated price range of Moderna’s COVID-19 vaccine. The vaccine is set between $32 and $37 per dose for certain customers, who are under cheaper pandemic pricing. Meanwhile, both Pfizer and BioNTech plan to charge customers with $19.50 per dose of their vaccines. The Moscow-based Gamaleya Institute is yet to announce its price per dose. Poonawalla said that SII will take manufacturing initiative to any of the over 100 vaccine candidates found effective